A new daily pill could be a more effective GLP-1 tablet for weight loss, according to a clinical trial that may pave the way for an improved non-injection alternative to Wegovy and Mounjaro. The drug, called orforglipron and manufactured by Eli Lilly, is prescribed for type 2 diabetes and targets the same GLP-1 receptors as oral semaglutide. At present, semaglutide is the only GLP-1 medication for type 2 diabetes available in pill form in the US. However, oral semaglutide has been shown to be less effective for weight loss than semaglutide injections — such as Ozempic and Wegovy — or tirzepatide injections such as Mounjaro. Participants received either 12mg or 36mg of orforglipron, or 7mg or 14mg of oral semaglutide, over the course of a year.

Source: Irish Examiner February 26, 2026 20:22 UTC